BETR — BetterLife Pharma Income Statement
0.000.00%
- CA$12.95m
- CA$17.13m
Annual income statement for BetterLife Pharma, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | -0.04 | 0 | 0 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19 | 20.2 | 10.7 | 9.4 | 2.64 |
Operating Profit | -19 | -20.2 | -10.7 | -9.4 | -2.64 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.6 | -36.4 | -12 | -9.37 | -2.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.6 | -36.4 | -12.2 | -9.37 | -2.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -19.6 | -36.4 | -12.2 | -9.02 | -2.89 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.6 | -36.4 | -12.2 | -9.02 | -2.89 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.66 | -0.305 | -0.158 | -0.105 | -0.032 |